A small clinical trial of 10 patients with early Alzheimer’s disease has shown that the memory loss and cognitive impairment can be reversed.
Not only were improvements sustained, but some patients returned to work, regained their ability to speak different languages, and showed an increase in brain matter volume after just a few months.
“All of these patients had either well-defined mild cognitive impairment, subjective cognitive impairment, or had been diagnosed with Alzheimer’s disease before beginning the program,” says one of the team, Dale Bredesen, University of California, Los Angeles. “Follow up testing showed some of the patients going from abnormal to normal.”
The study investigated the effects of a new kind of personalised treatment on the cognitive abilities of 10 patients who were experiencing age-related decline.
The treatment – called metabolic enhancement for neurodegeneration, or MEND – is based on 36 different factors, including changes in diet, exercise, and sleeping habits, plus the integration of certain drugs, vitamins, and brain stimulation therapy to their regular routine.
These lifestyle changes and treatments were sustained for five to 24 months, and the team from UCLA and the Buck Institute for Research on Ageing in California reports that many of the patients showed real, life-altering improvements as a result.
According to the researchers, this is the first study to objectively show that memory loss in patients can be reversed, and improvement sustained.
“The magnitude of improvement in these 10 patients is unprecedented, providing additional objective evidence that this programmatic approach to cognitive decline is highly effective,” says Bredesen.
Publishing their results in the journal Aging, the team hasn’t gone into much detail about how MEND works, probably because each treatment involves a complex combination of factors that has been specifically designed to treat just one individual, as each person’s version of Alzheimer’s appears to be different.
But they do mention something that all but one of the patients have in common – they are all at genetic risk for Alzheimer’s disease, carrying at least one copy of the APOE4 allele. Five of the patients are carrying two copies of APOE4, which gives them a 10- to 12-fold increased risk of developing the disease, the team explains.
This means there could be some benefit in getting tested for this genetic risk, because patients might finally be able to do something to stall the progression of the disease. Around 65 percent of Alzheimer’s cases in the US involve APOE4.
“We’re entering a new era,” says Bredesen. “The old advice was to avoid testing for APOE because there was nothing that could be done about it. Now we’re recommending that people find out their genetic status as early as possible so they can go on prevention.”
Learn more: Small trial shows memory loss from Alzheimer’s disease can be reversed
The Latest on: APOE4
[google_news title=”” keyword=”APOE4″ num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: APOE4
- Beyond Risk: Do Two APOE4 Alleles Always Mean Alzheimer's?on May 10, 2024 at 8:50 am
“Redefining APOE4 homozygosity as a genetic form of Alzheimer’s disease will have a substantial effect on Alzheimer’s disease diagnosis, research, and therapeutic development,” wrote Qin Xu, Zherui Liang, and Yadong Huang of the Gladstone Institute of Neurological Disease in San Francisco, in an editorial in Nature.
- Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlightson May 9, 2024 at 3:59 am
Closed an oversubscribed $95 million equity financing in March with Q1 2024 cash balance of $195.1 million at quarter-end, expected to provide runway into 2027 Completed in-license agreement with Cornell University for intellectual property rights,
- 6.7 million Americans at risk of genetic Alzheimer's with 95% strike rateon May 8, 2024 at 3:22 am
This means the APOE4 gene may no longer merely a risk factor but the driver behind a new stand-alone genetic Alzheimer's disease type that could impact up to 10 million Americans and more than 200 million people worldwide. "This gene has been known for ...
- APOE4 gene linked to early onset Alzheimer's, target for therapeutic interventionon May 8, 2024 at 12:20 am
A study published in Nature Medicine delineates how APOE4 homozygosity distinctly accelerates Alzheimer's disease pathology and biomarkers from the age of 55, suggesting a unique form of the disease and a potential focus for targeted therapies.
- One in 50 people is ‘highly likely’ to develop Alzheimer’s diseaseon May 7, 2024 at 5:30 pm
It revealed that more than 95 per cent of people aged 65 and above with two copies of the APOE4 gene went on to show early signs of the disease. They also tended to develop the condition earlier than those with other variants of the gene. Researchers said ...
- You're Practically Guaranteed to Get Alzheimer's If You Have This Genetic Varianton May 7, 2024 at 1:01 pm
Recent research indicates that people with two copies of the APOE4 gene are almost certain to exhibit signs of the neurological disease by their mid-60s.
- Scientists claim distinct genetic form of Alzheimer’s is extremely hereditaryon May 7, 2024 at 12:21 pm
S cientists have claimed to have found another distinct genetic form of Alzheimer’s disease that is extremely hereditary, to the point that "almost everyone" with two copies of genetic variant ApoE4 goes on to develop the disease.
- Some Alzheimer's cases may be caused by copies of a single gene, research showson May 6, 2024 at 10:59 am
Researchers have identified a genetic form of late-onset Alzheimer’s disease in people who inherit two copies of the APOE4 gene. The study marks a breakthrough.
via Bing News